Old Republic International
ORI
$39.66
+2.56%
Old Republic International Corporation is a diversified insurance underwriter operating through two primary segments: Specialty Insurance, which provides commercial property and liability coverage (including workers' compensation, commercial auto, inland marine, aviation, and financial indemnity) to commercial clients, and Title Insurance, which serves residential and commercial real estate transactions. The company is a long-established, conservatively managed underwriter with a nearly 100-year operating history and a listing dating to 1975, positioning it as a durable, dividend-focused value name in the Financial Services sector rather than a growth-oriented platform. The current investor narrative centers on the tension between the stock's defensive, income-generating profile (an unusually high dividend yield near 7%) and its persistent underperformance versus the broader market, with shares down roughly 3% over the trailing year against a 15.5% gain for the S&P 500. Debate among the thin analyst coverage revolves around whether depressed underwriting conditions in title insurance and commercial lines, combined with a payout ratio above 80%, represent a value opportunity or a warning sign on dividend sustainability and earnings quality.…
ORI
Old Republic International
$39.66
Investment Opinion: Should I buy ORI Today?
Rating: Hold. ORI is a conservatively financed, cash-generative insurer trading at a genuinely low 11.89x trailing and 12.08x forward P/E with a 7.03% dividend yield, but the stock's -18.59% one-year relative underperformance versus SPY and its position at just 29.6% of the 52-week range argue against chasing it before dividend coverage and underwriting trends are confirmed. The two-analyst 'buy' consensus with a $43.50 average target (9.7% upside) is a modest positive but too thin a signal to anchor a Buy.
Supporting evidence is mixed but leans value-positive: the 15.83% ROE and 10.30% net margin show profitability, the 0.269 debt-to-equity and 3.40 current ratio show balance-sheet strength, the 9.56x P/CF implies a ~10.5% cash yield, and the 0.726 PEG suggests the stock is inexpensive relative to growth. Against that, the 83.6% payout ratio limits flexibility, the 12.08x forward P/E versus 11.89x trailing implies flat earnings expectations, and the 1.22x P/S reflects a mature, slow-growth top line with consensus revenue of ~$10.73 billion and minimal dispersion.
The biggest risks that could invalidate the thesis are a dividend cut (83.6% payout), a title-insurance volume slump tied to weak real estate, and continued relative underperformance (-20.27% YTD versus SPY). This Hold would upgrade to Buy if the dividend is reaffirmed with underwriting margins holding above 13% operating margin and the stock stabilizes above the $36.65 52-week low; it would downgrade to Sell if the payout ratio rises above 90% or the stock breaks $36.65 on volume. Valuation verdict: fairly valued to modestly undervalued relative to its own earnings power, but not yet a compelling buy given the unresolved dividend-sustainability question.
Sign up to view all
ORI 12-Month Price Forecast
ORI presents a fairly valued, income-heavy opportunity rather than a growth story: the 11.89x P/E, 1.88x P/B, and 15.83% ROE are attractive, and the 7.03% yield is well above typical financial-sector payouts, but the 83.6% payout ratio and flat forward earnings expectations (12.08x forward versus 11.89x trailing) cap upside. The stock's -18.59% one-year relative underperformance and position near the bottom of its 52-week range reflect genuine market skepticism about dividend durability and title-insurance cyclicality, not just neglect. The base case (50% probability) assumes the dividend holds and the stock converges toward the $43.50 average target, with the 7% yield doing most of the work. I would upgrade to bullish if the next earnings report shows the payout ratio falling below 80% with operating margins above 13%, and downgrade to bearish if the dividend is cut or the $36.65 low breaks decisively.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Old Republic International's 12-month outlook, with a consensus price target around $43.50 and implied upside of +9.7% versus the current price.
Average Target
$43.50
0 analysts
Implied Upside
+9.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$39 - $48
Analyst target range
Coverage is thin, with only 2 analysts covering Old Republic. The consensus recommendation is "buy" with a recommendation mean of 2.33 (on a scale where lower is more bullish), and the average target price is $43.50 — implying approximately 9.7% upside from the current $39.66. The bullish tilt from such a small sample should be treated cautiously, as two analysts provide limited statistical signal and the consensus leans modestly positive rather than strongly conviction-driven.
The target range spans $39.00 to $48.00, a spread of roughly 23% around the average, which signals meaningful uncertainty. The high target of $48.00 (about 21% above current) likely assumes multiple expansion toward the higher end of the insurer's historical band and improved underwriting results, while the low target of $39.00 (roughly 1.7% below current) prices in continued margin pressure and a stagnant premium cycle. Consensus EPS estimates are tightly clustered at $3.335 to $3.367 (average $3.351), indicating high confidence in near-term earnings but little differentiation in growth expectations. With only two analysts and no institutional ratings data showing recent upgrades or downgrades, price discovery is likely less efficient, and the stock may be more susceptible to volatility around earnings and dividend announcements.
Bulls vs Bears: ORI Investment Factors
The bear case currently has stronger evidence: ORI's -18.59% one-year relative strength gap to SPY, its position at just 29.6% of the 52-week range, and an 83.6% payout ratio all point to a stock the market is actively de-rating despite a 7% yield. The bull case rests on valuation and balance-sheet quality — 11.89x earnings, 1.88x book, 15.83% ROE, and 0.269 debt-to-equity — which are genuinely attractive but have not been sufficient to halt the decline. The single most important tension is dividend sustainability: if the 7.03% payout is proven safe through the current underwriting soft cycle, the stock is deeply undervalued; if it is cut or growth stalls, the yield trap becomes self-reinforcing. Resolution of that question, likely via the next earnings report and any dividend announcement, will determine whether ORI is a value opportunity or a value trap.
Bullish
- Deep value multiple with high ROE: ORI trades at 11.89x trailing and 12.08x forward earnings and 1.88x book, yet generates a 15.83% ROE and 10.30% net margin. A sub-12x P/E for a nearly century-old underwriter earning mid-teens returns on equity is a classic value setup, and the PEG ratio of 0.726 (below 1.0) suggests the market is underpricing earnings relative to growth.
- 7% dividend yield with covered payout: The 7.03% dividend yield is unusually high for a financial-sector name and is backed by a 10.30% net margin and 9.56x price-to-cash-flow, implying cash flow equals roughly 10.5% of market cap. The 83.6% payout ratio is elevated but still earnings-covered, making the income case the strongest single pillar of the bull thesis.
- Fortress balance sheet, low leverage: Debt-to-equity of 0.269 and a current ratio of 3.40 indicate a conservatively financed insurer with ample liquidity. For a company whose risk is underwriting cyclicality rather than solvency, this balance sheet provides a cushion that supports both the dividend and the ability to hold reserves through a soft premium cycle.
- Analyst upside and buy consensus: The two covering analysts carry a 'buy' consensus (mean 2.33) with an average target of $43.50, about 9.7% above the $39.66 price, and a high target of $48.00 implying 21% upside. Consensus EPS estimates are tightly clustered at $3.335–$3.367, signaling high confidence in near-term earnings stability.
Bearish
- Persistent relative underperformance: ORI is down 3.06% over one year versus a 15.53% gain for SPY, a relative strength gap of -18.59%, and it lags in every window (-4.25% 1M, -8.80% 3M, -14.29% 6M, -20.27% YTD). This uniform underperformance indicates the market is actively repricing the stock lower, not merely ignoring it.
- High payout ratio limits flexibility: An 83.6% payout ratio leaves only a thin cushion of retained earnings, and with a 10.30% net margin the dividend is covered but not comfortably. Any underwriting deterioration in title insurance or commercial lines would force a choice between cutting the 7% yield — which would likely trigger a sharp selloff — or underinvesting in the business.
- Weak technical structure near lows: At $39.66 the stock sits at only 29.6% of its 52-week range ($36.65–$46.76), just 7.6% above the 52-week low, with a 21.36% max drawdown from prior highs. The stair-stepping decline of -3.03% (1M), -6.11% (3M), and -6.81% (6M) shows lower highs rather than a base, and a break of $36.65 would confirm the downtrend.
- Thin coverage weakens price discovery: Only two analysts cover ORI, with a 23% spread between the $39.00 low and $48.00 high target. Such thin coverage means the 'buy' consensus carries limited statistical signal, and the stock is more vulnerable to sharp moves around earnings or dividend announcements when few voices anchor expectations.
ORI Technical Analysis
Old Republic is in a sustained, range-bound downtrend rather than a clean recovery. The stock has fallen 3.06% over the trailing year and 8.34% year-to-date, and at $39.66 it sits at roughly 29.6% of its 52-week range of $36.65 to $46.76 — meaning it is trading in the lower third of its annual band, closer to the floor than the ceiling. That positioning signals a stock lacking momentum and vulnerable to further mean-reversion pressure rather than one exhibiting overextension; the 21.36% max drawdown confirms meaningful capital erosion from prior highs near $46.76.
Short-term momentum is weak and diverging negatively from an already soft long-term trend. The stock is down 3.03% over the past month, 6.11% over three months, and 6.81% over six months, a sequence that shows persistent, stair-stepping declines rather than a single shock. Relative strength is uniformly negative across every window — minus 4.25% versus SPY over one month, minus 8.80% over three months, and minus 18.59% over one year — indicating the stock is losing ground to the market even as the market itself advances. The lone bright spot is the most recent session, a 2.56% single-day pop from $38.67 to $39.66, which may reflect short covering or an oversold bounce, but a single up-day does not reverse a six-month pattern of lower highs.
Key technical levels are well defined. Support rests at the 52-week low of $36.65, roughly 7.6% below the current price; a breakdown there would confirm the downtrend and likely trigger further selling. Resistance sits at the 52-week high of $46.76, about 17.9% above current levels, and a breakout above that would be required to invalidate the bearish structure. The stock's beta of 0.587 means it is roughly 41% less volatile than the market, which is consistent with a defensive insurance value name — this dampens drawdown risk in absolute terms but also caps upside participation, and position sizing should account for the fact that this is a low-beta, income-oriented holding rather than a high-momentum trade.
Beta
0.59
0.59x market volatility
Max Drawdown
-21.4%
Largest decline past year
52-Week Range
$37-$47
Price range past year
Annual Return
-3.1%
Cumulative gain past year
| Period | ORI Return | S&P 500 |
|---|---|---|
| 1m | -3.0% | +0.2% |
| 3m | -6.1% | +2.9% |
| 6m | -6.8% | +8.4% |
| 1y | -3.1% | +14.9% |
| ytd | -8.3% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ORI Fundamental Analysis
Revenue trajectory is difficult to assess precisely because the provided quarterly financials, income statement, and revenue segment data are empty, but the available valuation and analyst inputs imply a mature, slow-growth profile. The consensus revenue estimate of approximately $10.73 billion (range $10.69 billion to $10.77 billion) suggests analysts expect a stable top line with minimal dispersion, consistent with a commercial lines underwriter whose growth is tied to premium pricing cycles and exposure units rather than rapid expansion. With a market cap of roughly $11.1 billion and a price-to-sales ratio of 1.22, the market is valuing the business at a modest multiple of sales, implying investors do not expect accelerating growth; the investment case therefore rests on underwriting discipline and capital return rather than revenue expansion.
The company is solidly profitable, with a net margin of 10.30%, an operating margin of 13.02%, and a gross margin of 50.35%. Trailing EPS of $0.084 appears inconsistent with the $39.66 share price and the 11.89x trailing P/E, suggesting the reported EPS figure is likely a data artifact or a non-annualized/partial-period measure; the more reliable signal is the forward EPS estimate of $3.35, which implies a forward P/E of 12.08x and a normalized earnings base far above the trailing figure. Return on equity of 15.83% and return on assets of 3.12% are respectable for a diversified insurer, indicating the company earns adequate returns on its capital base. The 83.6% payout ratio is elevated and bears watching, but with a 10.3% net margin the dividend appears covered by earnings, albeit with limited cushion.
Balance sheet and cash flow metrics point to a conservatively financed, cash-generative business. Debt-to-equity of 0.269 is low for a financial company, and a current ratio of 3.40 indicates ample short-term liquidity. The price-to-cash-flow ratio of 9.56 suggests the company generates cash flow at roughly 10.5% of its market value, a healthy cash yield that supports the dividend and internal funding of growth without heavy reliance on external financing. Free cash flow and detailed cash flow statement data are not available in the provided inputs, but the combination of low leverage, strong liquidity, and a sub-10x P/CF multiple is consistent with a financially sound underwriter whose primary risk is earnings cyclicality rather than solvency.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ORI Overvalued?
Because net income is positive (net margin 10.30%), the P/E ratio is the appropriate primary metric. The stock trades at 11.89x trailing earnings and 12.08x forward earnings — an unusually narrow gap that implies the market expects essentially flat earnings growth, with forward EPS of $3.35 barely above the implied trailing base. This compressed trailing-to-forward spread signals that investors are not pricing in an earnings acceleration; instead, the valuation reflects a mature, cyclical insurer trading at a low-teens multiple.
On peer comparison, the stock's 11.89x P/E and 1.88x price-to-book are modest for a diversified insurance company, and its 1.22x P/S and 0.92x EV/Sales are low in absolute terms. The PEG ratio of 0.726 — below 1.0 — suggests the stock is inexpensive relative to its growth rate, a classic value signal. However, industry-average multiples are not provided in the valuation data, so a precise premium/discount spread cannot be quantified; qualitatively, a sub-12x P/E with a 15.8% ROE and a 7% dividend yield is consistent with a value-oriented insurer trading at a discount, which may be justified by the title insurance segment's sensitivity to a weak real estate market and the high 83.6% payout ratio.
Historical ratio data is not available in the provided inputs, so the stock's position within its own historical P/E or P/B band cannot be precisely established. That said, the current 11.89x trailing P/E and 1.88x P/B are low in absolute terms for an insurer with a 15.8% ROE, and the 7.03% dividend yield is high relative to typical financial-sector yields — a combination that historically has signaled either deep value or market skepticism about earnings durability. Absent historical context, the prudent interpretation is that the market is pricing in caution around underwriting margins and dividend coverage rather than optimism.
PE
11.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on earnings quality and dividend coverage. The 83.6% payout ratio leaves only 16.4% of earnings retained, and with a 10.30% net margin the cushion is thin; a modest decline in underwriting profitability would pressure the 7.03% yield. The reported trailing EPS of $0.084 is inconsistent with the $39.66 price and 11.89x P/E, suggesting data quality issues that complicate fundamental verification, while the forward EPS estimate of $3.35 implies the market is relying on normalized earnings that have not yet been confirmed in the provided financials. Revenue concentration in Specialty Insurance and cyclical title insurance exposure add operational sensitivity to commercial premium pricing and real estate transaction volumes.
Market and competitive risks are dominated by valuation compression and sector rotation. At 11.89x trailing and 12.08x forward earnings with a PEG of 0.726, ORI is already cheap, but cheap insurers can stay cheap if underwriting margins deteriorate; the 1.88x P/B offers limited downside protection if book value erodes. The stock's beta of 0.587 dampens absolute volatility but has not prevented a -18.59% one-year relative underperformance versus SPY, and the -20.27% YTD relative gap shows capital rotating away from defensive value names. Thin analyst coverage (two analysts, 23% target spread) increases susceptibility to sharp repricing around earnings or dividend news.
Worst-case scenario: a soft commercial premium cycle combines with a weak housing market that depresses title insurance volumes, pushing underwriting margins below the current 13.02% operating level and forcing management to cut the 7.03% dividend to protect capital. In that chain, the stock would likely retest and break the 52-week low of $36.65, a decline of roughly 7.6% from $39.66, and could extend toward the $36 area or lower if the dividend cut triggers income-fund selling. The 21.36% max drawdown already observed shows the stock can lose over a fifth of its value from prior highs; a repeat from current levels would imply a price near $31, roughly -22%.
FAQ
The most severe risk is dividend sustainability: an 83.6% payout ratio leaves little cushion, and a cut to the 7.03% yield would likely trigger income-fund selling. Second is underwriting cyclicality, particularly title insurance exposure to a weak housing market and commercial premium pricing, which could push the 13.02% operating margin lower. Third is valuation compression and relative underperformance, evidenced by the -18.59% one-year and -20.27% YTD gaps versus SPY, which could persist if capital stays rotated away from defensive value names. Fourth is thin analyst coverage (two analysts, $39.00–$48.00 target spread), which increases the risk of sharp repricing around earnings or dividend announcements.
The 12-month forecast has three scenarios: a 25% bull case targeting $46.76–$48.00 on dividend reaffirmation and margin stabilization, a 50% base case targeting $39.00–$43.50 on consensus EPS of ~$3.35 and a maintained dividend, and a 25% bear case targeting $36.65–$39.00 on a dividend cut or margin compression. The base case is most likely, with the key assumption being that the 83.6% payout ratio remains covered and the stock converges toward the $43.50 analyst average target. In that scenario, total return is dominated by the 7.03% dividend yield, with limited capital appreciation given flat forward earnings expectations at 12.08x versus 11.89x trailing.
ORI appears modestly undervalued on absolute metrics: 11.89x trailing and 12.08x forward P/E, 1.88x P/B, 1.22x P/S, and 0.92x EV/Sales are low for an insurer earning a 15.83% ROE. The PEG ratio of 0.726 below 1.0 reinforces the value signal, and the 9.56x P/CF implies a cash yield of roughly 10.5%. However, the narrow gap between trailing and forward multiples implies the market expects flat earnings, and without historical ratio data a precise discount to ORI's own history cannot be quantified. The market appears to be pricing in caution around the 83.6% payout ratio and title-insurance cyclicality rather than optimism, so the stock is fairly valued to modestly undervalued rather than deeply discounted.
From a risk/reward perspective, ORI offers roughly 9.7% upside to the $43.50 analyst average target plus a 7.03% dividend yield, against downside to the $36.65 52-week low of about 7.6%. The valuation is undemanding at 11.89x trailing and 12.08x forward earnings with a 0.726 PEG and 1.88x book, and the balance sheet is strong with 0.269 debt-to-equity. However, the 83.6% payout ratio is the key swing factor: if the dividend is safe, the stock is cheap; if it is cut, the yield trap could produce a sharp decline. It is a reasonable buy for income-oriented investors with a medium-term horizon who can tolerate flat capital appreciation, but less attractive for growth investors given the -18.59% one-year relative underperformance versus SPY.
ORI is better suited to long-term, income-oriented holding than short-term trading. Its beta of 0.587 dampens volatility, the 7.03% dividend yield rewards patience, and the 15.83% ROE and 0.269 debt-to-equity support a durable business, but the -18.59% one-year relative underperformance and weak technical structure near the $36.65 low offer little short-term momentum to trade. Earnings visibility is moderate given tightly clustered consensus EPS of $3.335–$3.367, but thin analyst coverage and title-insurance cyclicality add event risk around earnings. A suggested minimum holding period is 12–18 months to capture at least one full dividend cycle and allow the dividend-sustainability question to resolve.